Wolford JE, Bai J, Moore KN, Kristeleit R, et al. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma. Gynecol Oncol 2020 Mar 13. pii: S0090-8258(20)30176.
PMID: 32173049